Cargando…

The acute effect of metabolic cofactor supplementation: a potential therapeutic strategy against non‐alcoholic fatty liver disease

The prevalence of non‐alcoholic fatty liver disease (NAFLD) continues to increase dramatically, and there is no approved medication for its treatment. Recently, we predicted the underlying molecular mechanisms involved in the progression of NAFLD using network analysis and identified metabolic cofac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Cheng, Bjornson, Elias, Arif, Muhammad, Tebani, Abdellah, Lovric, Alen, Benfeitas, Rui, Ozcan, Mehmet, Juszczak, Kajetan, Kim, Woonghee, Kim, Jung Tae, Bidkhori, Gholamreza, Ståhlman, Marcus, Bergh, Per‐Olof, Adiels, Martin, Turkez, Hasan, Taskinen, Marja‐Riitta, Bosley, Jim, Marschall, Hanns‐Ulrich, Nielsen, Jens, Uhlén, Mathias, Borén, Jan, Mardinoglu, Adil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184219/ https://www.ncbi.nlm.nih.gov/pubmed/32337855 http://dx.doi.org/10.15252/msb.209495

Ejemplares similares

Kinetic Studies to Elucidate Impaired Metabolism of Triglyceride-rich Lipoproteins in Humans
por: Adiels, Martin, et al.
Publicado: (2015)

Characterization of different fat depots in NAFLD using inflammation-associated proteome, lipidome and metabolome
por: Lovric, Alen, et al.
Publicado: (2018)

Informing Pharmacokinetic Models With Physiological Data: Oral Population Modeling of L-Serine in Humans
por: Bosley, J. R., et al.
Publicado: (2021)

Classification of clear cell renal cell carcinoma based on PKM alternative splicing
por: Li, Xiangyu, et al.
Publicado: (2020)

Stratification of patients with clear cell renal cell carcinoma to facilitate drug repositioning
por: Li, Xiangyu, et al.
Publicado: (2021)

TCSBN: a database of tissue and cancer specific biological networks
por: Lee, Sunjae, et al.
Publicado: (2018)

Applications of Genome-Wide Screening and Systems Biology Approaches in Drug Repositioning
por: Mohammadi, Elyas, et al.
Publicado: (2020)

Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study
por: Björnson, Elias, et al.
Publicado: (2023)

Personal model‐assisted identification of NAD(+) and glutathione metabolism as intervention target in NAFLD
por: Mardinoglu, Adil, et al.
Publicado: (2017)

Genome-scale metabolic modelling of the human gut microbiome reveals changes in the glyoxylate and dicarboxylate metabolism in metabolic disorders
por: Proffitt, Ceri, et al.
Publicado: (2022)

The Potential Use of Metabolic Cofactors in Treatment of NAFLD
por: Mardinoglu, Adil, et al.
Publicado: (2019)

Improved Estimation of Human Lipoprotein Kinetics with Mixed Effects Models
por: Berglund, Martin, et al.
Publicado: (2015)

Understanding the Representative Gut Microbiota Dysbiosis in Metformin-Treated Type 2 Diabetes Patients Using Genome-Scale Metabolic Modeling
por: Rosario, Dorines, et al.
Publicado: (2018)

ESS: A Tool for Genome-Scale Quantification of Essentiality Score for Reaction/Genes in Constraint-Based Modeling
por: Zhang, Cheng, et al.
Publicado: (2018)

Discovery of therapeutic agents for prostate cancer using genome-scale metabolic modeling and drug repositioning
por: Turanli, Beste, et al.
Publicado: (2019)

Metabolic Network-Based Identification and Prioritization of Anticancer Targets Based on Expression Data in Hepatocellular Carcinoma
por: Bidkhori, Gholamreza, et al.
Publicado: (2018)

Characterization of an in vitro steatosis model simulating activated de novo lipogenesis in MAFLD patients
por: Kim, Woonghee, et al.
Publicado: (2023)

Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans
por: Borén, Jan, et al.
Publicado: (2020)

Characterization of heterogeneous redox responses in hepatocellular carcinoma patients using network analysis
por: Benfeitas, Rui, et al.
Publicado: (2018)

Integrative transcriptomic analysis of tissue-specific metabolic crosstalk after myocardial infarction
por: Arif, Muhammad, et al.
Publicado: (2021)

Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?
por: Taskinen, Marja-Riitta, et al.
Publicado: (2016)

Systems Analysis Reveals Ageing-Related Perturbations in Retinoids and Sex Hormones in Alzheimer’s and Parkinson’s Diseases
por: Lam, Simon, et al.
Publicado: (2021)

New Challenges to Study Heterogeneity in Cancer Redox Metabolism
por: Benfeitas, Rui, et al.
Publicado: (2017)

Contribution of intestinal triglyceride-rich lipoproteins to residual atherosclerotic cardiovascular disease risk in individuals with type 2 diabetes on statin therapy
por: Taskinen, Marja-Riitta, et al.
Publicado: (2023)

Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single‐centre randomized controlled study
por: Matikainen, Niina, et al.
Publicado: (2018)

A continuous-time adaptive particle filter for estimations under measurement time uncertainties with an application to a plasma-leucine mixed effects model
por: Krengel, Annette, et al.
Publicado: (2013)

Current Status of COVID-19 Therapies and Drug Repositioning Applications
por: Altay, Ozlem, et al.
Publicado: (2020)

Multi-omics approaches for revealing the complexity of cardiovascular disease
por: Doran, Stephen, et al.
Publicado: (2021)

Longitudinal plasma protein profiling of newly diagnosed type 2 diabetes
por: Gummesson, Anders, et al.
Publicado: (2020)

Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD
por: Taskinen, Marja-Riitta, et al.
Publicado: (2019)

The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans
por: Borén, Jan, et al.
Publicado: (2020)

Causes and Consequences of Hypertriglyceridemia
por: Packard, Chris J., et al.
Publicado: (2020)

Dietary Fructose and the Metabolic Syndrome
por: Taskinen, Marja-Riitta, et al.
Publicado: (2019)

Prediction of drug candidates for clear cell renal cell carcinoma using a systems biology-based drug repositioning approach
por: Li, Xiangyu, et al.
Publicado: (2022)

Open MoA: revealing the mechanism of action (MoA) based on network topology and hierarchy
por: Liao, Xinmeng, et al.
Publicado: (2023)

Personalized Cardiovascular Disease Prediction and Treatment—A Review of Existing Strategies and Novel Systems Medicine Tools
por: Björnson, Elias, et al.
Publicado: (2016)

Postprandial metabolism of apolipoproteins B48, B100, C-III, and E in humans with APOC3 loss-of-function mutations
por: Taskinen, Marja-Riitta, et al.
Publicado: (2022)

A Gene Co-Expression Network-Based Drug Repositioning Approach Identifies Candidates for Treatment of Hepatocellular Carcinoma
por: Yuan, Meng, et al.
Publicado: (2022)

ApoCIII-Enriched LDL in Type 2 Diabetes Displays Altered Lipid Composition, Increased Susceptibility for Sphingomyelinase, and Increased Binding to Biglycan
por: Hiukka, Anne, et al.
Publicado: (2009)

Addressing the heterogeneity in liver diseases using biological networks
por: Lam, Simon, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_82ho333ufnm6fsib00ge0q0lc3